Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial by Subbiah, Vivek, MD, Lassen, Ulrik, Prof, Élez, Elena, MD, Italiano, Antoine, Prof, Curigliano, Giuseppe, Prof, Javle, Milind, Prof, de Braud, Filippo, Prof, Prager, Gerald W, Prof, Greil, Richard, Prof, Stein, Alexander, MD, Fasolo, Angelica, MD, Schellens, Jan H M, Prof, Wen, Patrick Y, Prof, Viele, Kert, PhD, Boran, Aislyn D, PhD, Gasal, Eduard, MD, Burgess, Paul, MSci, Ilankumaran, Palanichamy, PhD, Wainberg, Zev A, Prof

Get full text

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study by Gainor, Justin F, MD, Curigliano, Giuseppe, Prof, Kim, Dong-Wan, Prof, Lee, Dae Ho, Prof, Besse, Benjamin, Prof, Baik, Christina S, MD, Doebele, Robert C, MD, Cassier, Philippe A, MD, Lopes, Gilberto, MD, Tan, Daniel S W, MD, Garralda, Elena, MD, Paz-Ares, Luis G, Prof, Cho, Byoung Chul, Prof, Gadgeel, Shirish M, MD, Thomas, Michael, Prof, Liu, Stephen V, MD, Taylor, Matthew H, MD, Mansfield, Aaron S, MD, Zhu, Viola W, MD, Clifford, Corinne, MS, Zhang, Hui, PhD, Palmer, Michael, PhD, Green, Jennifer, BS, Turner, Christopher D, MD, Subbiah, Vivek, MD

Get full text

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, ph... by Wildiers, Hans, PhD, Tryfonidis, Konstantinos, MD, Dal Lago, Lissandra, MD, Vuylsteke, Peter, MD, Curigliano, Giuseppe, Prof, Waters, Simon, MD, Brouwers, Barbara, MD, Altintas, Sevilay, PhD, Touati, Nathan, MS, Cardoso, Fatima, MD, Brain, Etienne, MD

Get full text

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study by Li, Bob T, MD, Meric-Bernstam, Funda, Prof, Bardia, Aditya, MD, Naito, Yoichi, MD, Siena, Salvatore, Prof, Aftimos, Philippe, MD, Anderson, Ian, MD, Curigliano, Giuseppe, Prof, de Miguel, Maria, MD, Kalra, Maitri, MD, Oh, Do-Youn, Prof, Park, Joon Oh, Prof, Postel-Vinay, Sophie, MD, Rha, Sun Young, Prof, Satoh, Taroh, Prof, Spanggaard, Iben, MD, Michelini, Flavia, PhD, Smith, Ann, MSc, Machado, Karime Kalil, MD, Saura, Cristina, MD

Get full text

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-... by Meattini, Icro, MD, Becherini, Carlotta, MD, Caini, Saverio, PhD, Coles, Charlotte E, Prof, Cortes, Javier, MD, Curigliano, Giuseppe, Prof, de Azambuja, Evandro, MD, Isacke, Clare M, Prof, Harbeck, Nadia, MD, Kaidar-Person, Orit, MD, Marangoni, Elisabetta, PhD, Offersen, Birgitte V, Prof, Rugo, Hope S, MD, Salvestrini, Viola, MD, Visani, Luca, MD, Morandi, Andrea, PhD, Lambertini, Matteo, MD, Poortmans, Philip, Prof, Livi, Lorenzo, Prof

Get full text

National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis by Duggan, Catherine, PhD, Trapani, Dario, MD, Ilbawi, André M, MD, Fidarova, Elena, MD, Laversanne, Mathieu, MSc, Curigliano, Giuseppe, MD, Bray, Freddie, PhD, Anderson, Benjamin O, Prof

Get full text

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox by Dubsky, Peter, MD, Pinker, Katja, Prof, Cardoso, Fatima, MD, Montagna, Giacomo, MD, Ritter, Mathilde, MD, Denkert, Carsten, Prof, Rubio, Isabel T, MD, de Azambuja, Evandro, MD, Curigliano, Giuseppe, MD, Gentilini, Oreste, MD, Gnant, Michael, Prof, Günthert, Andreas, MD, Hauser, Nik, PhD, Heil, Joerg, MD, Knauer, Michael, MD, Knotek-Roggenbauerc, Mona, MSc, Knox, Susan, MA, Kovacs, Tibor, MD, Kuerer, Henry M, Prof, Loibl, Sibylle, Prof, Mannhart, Meinrad, MD, Meattini, Icro, MD, Penault-Llorca, Frederique, Prof, Radosevic-Robin, Nina, MD, Sager, Patrizia, MD, Španić, Tanja, PhD, Steyerova, Petra, MD, Tausch, Christoph, MD, Peeters, Marie-Jeanne T F D Vrancken, MD, Weber, Walter P, MD, Cardoso, Maria J, MD, Poortmans, Philip, Prof

Get full text

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study by Pivot, Xavier, Prof, Gligorov, Joseph, MD, Müller, Volkmar, Prof, Barrett-Lee, Peter, Prof, Verma, Sunil, Prof, Knoop, Ann, MD, Curigliano, Giuseppe, MD, Semiglazov, Vladimir, Prof, López-Vivanco, Guillermo, MD, Jenkins, Valerie, DPhil, Scotto, Nana, MD, Osborne, Stuart, MSc, Fallowfield, Lesley, Prof

Get full text

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial by Loi, Sherene, Prof, Giobbie-Hurder, Anita, MS, Gombos, Andrea, MD, Bachelot, Thomas, Prof, Hui, Rina, Prof, Curigliano, Giuseppe, Prof, Campone, Mario, Prof, Biganzoli, Laura, MD, Bonnefoi, Hervé, Prof, Jerusalem, Guy, Prof, Bartsch, Rupert, Prof, Rabaglio-Poretti, Manuela, MD, Kammler, Roswitha, Maibach, Rudolf, PhD, Smyth, Mark J, Prof, Di Leo, Angelo, MD, Colleoni, Marco, MD, Viale, Giuseppe, Prof, Regan, Meredith M, ScD, André, Fabrice, Prof

Get full text